Traders are a little more bearish on the company recently as evidenced by the uptick in short interest. The stock realized a rise in short interest of 90.99% as of the latest report on August 31, 2017. Short shares increased 55,005 over that timeframe. Days to cover decreased from 9.0 to 3.0 and the short interest percentage is 0.00% as of August 31.
These firms have modified their investment in PRQR. Janus Capital Management LLC reduced its stake by selling 10,039 shares a decrease of 2.5% as of 03/31/2017. Janus Capital Management LLC now controls 383,821 shares with a value of $1,919,000. The total value of its holdings decreased 0.6%. As of quarter end Redmile Group, LLC had acquired 43,050 shares growing its stake by 2.8%. The value of the investment in PRQR went from $7,766,000 to $8,301,000 a change of $535,000 quarter to quarter.
As of the end of the quarter Clearbridge Investments, LLC had bought a total of 804 shares growing its holdings by 0.2%. The value of the total investment in ProQR Therapeutics N.V. – Ordin increased from $2,497,000 to $2,601,000 a change of 4.2% since the last quarter. As of quarter end Artal Group S.a. had acquired 100,000 shares growing its position 25.0%. The value in dollars increased from $2,000,000 to $2,600,000 increasing 30.0% quarter over quarter.
The company is now up since yesterday’s close of 5. Shares last traded at $5.25 which is a tad above $5.12, the stock’s 50 day moving average and which is just a bit higher than the 200 day moving average of $5.00. The 50 day moving average moved up $0.13 whereas the 200 day average was up by +5.0341%.
As of the last earnings report the EPS was $-2.07 and is estimated to be $-2.14 for the current year with 24,105,000 shares presently outstanding. Next quarter’s EPS is forecasted to be $-0.53 with next year’s EPS anticipated to be $-1.70.
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is involved in the discovery and development of Ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA). The Company designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. The Business’s product candidates include QR-010 and QR-110. The Company is focusing on developing QRX- 911, QRX- 021, QRX- 313 for Epidermolysis bullosa, QRX- 704 for Huntington’s disease, QRX- 812, QRX- 411 for Usher syndrome, QRX- 504 for Fuchs, QRX- 604 for Friedreich’s ataxia and QRX- 203 for Alzheimer’s disease..